奈福泮能否在初次全膝关节置换术后提供镇痛效果并减少吗啡用量?一项前瞻性、双盲、随机对照试验
该双盲随机对照试验比较了初次单侧全膝关节置换术后持续静脉输注奈福泮80 mg 24小时与安慰剂的镇痛效果。奈福泮组术后6小时静息VAS评分显著低于安慰剂组,0-48小时总吗啡用量显著减少37%,但其他时间点及运动VAS无显著差异,不良事件与功能结局无差异。
要点
- 奈福泮组术后6小时静息VAS评分显著低于安慰剂组(20.3±27.3 vs 35±24.3,P=.01)。
- 奈福泮组0-48小时总吗啡用量较安慰剂组显著减少37%(5.3±4.5 vs 8.4±7.5 mg,P=.03)。
- 其他时间点及运动VAS、不良事件、功能结局和满意度两组间无显著差异。
核心结论
- 全膝关节置换术后24小时持续输注奈福泮作为多模式镇痛的一部分产生了显著镇痛效果,但仅限于术后前6小时。
- 术后48小时吗啡用量显著减少,奈福泮是当代全膝关节置换术后疼痛控制的有用药物。
研究设计与样本
- 双盲、随机对照试验,纳入接受单侧初次全膝关节置换术的患者,比较24小时持续静脉输注奈福泮80 mg与安慰剂输注。
- 主要结局为术后48小时内静息和运动100 mm视觉模拟量表(VAS)疼痛评分。
主要发现
- 奈福泮组术后6小时静息VAS评分显著低于安慰剂组(20.3±27.3 vs 35±24.3,P=.01),其他时间点及运动VAS无显著差异。
- 奈福泮组0-48小时总吗啡用量较安慰剂组显著减少37%(5.3±4.5 vs 8.4±7.5 mg,P=.03)。
- 奈福泮组止吐药用量较安慰剂组减少61%,但未达统计学显著(0.8±2.3 vs 2.0±3.8 mg,P=.08)。
- 两组不良事件、功能结局(行走时间、计时起立行走测试、术后24和48小时膝关节活动度、出院时间)和满意度评分无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: One of the most undesirable results after total knee arthroplasty (TKA) is severe immediate postoperative pain, resulting in patient dissatisfaction. We aimed to evaluate nefopam's analgesic efficacy after primary TKA along with related outcomes, including morphine consumption and adverse events. METHODS: We conducted a double-blind, randomized controlled trial of patients undergoing unilateral primary TKA, comparing 24 hours of 80 mg of continuous intravenous nefopam to placebo infusion. A 100-mm Visual Analog Scale (VAS) for pain-at-rest and in-motion ≤48 hours was the primary outcome measure. Secondary outcomes were morphine and antiemetic consumption, adverse events, and functional outcomes: time-to-walk, timed up-and-go test, postoperative knee range of motion at 24 and 48 hours, time-to-discharge, and patient satisfaction scores. RESULTS: Patients in the nefopam group had significantly lower VAS at rest 6 hours postop (20.3 ± 27.3 vs 35 ± 24.3, P = .01). Other timepoints and in-motion VAS did not significantly differ. Total morphine consumption (0-48 hours) was 37% less, significantly lower, in the nefopam group (5.3 ± 4.5 vs 8.4 ± 7.5 mg, P = .03). Antiemetic consumption was also 61% lower in the nefopam group but not statistically significant (0.8 ± 2.3 vs 2.0 ± 3.8 mg, P = .08). There were no variations in adverse events, functional outcomes, and satisfaction scores between groups. CONCLUSION: Continuous nefopam administration as part of multimodal analgesia for 24 hours post-TKA produced a significant analgesic effect but only within the first 6 hours. However, there was a notable reduction in morphine use 48 hours postop. Nefopam is a useful agent for contemporary pain control after TKA. LEVEL OF EVIDENCE: Therapeutic Level I.
引用
- Pinsornsak P, Sukkarnkosol S, Boontanapibul K, et al. Does Nefopam Provide Analgesic Effect and Reduce Morphine Consumption After Primary Total Knee Arthroplasty? A Prospective, Double-Blind, Randomized Controlled Trial. J Arthroplasty. 2022. PMID: 35121091. doi:10.1016/j.arth.2022.01.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。